Nothing Special   »   [go: up one dir, main page]

WO2005112564A3 - Germline and sequence variants of humanized antibodies and methods of making and using them - Google Patents

Germline and sequence variants of humanized antibodies and methods of making and using them Download PDF

Info

Publication number
WO2005112564A3
WO2005112564A3 PCT/US2005/012662 US2005012662W WO2005112564A3 WO 2005112564 A3 WO2005112564 A3 WO 2005112564A3 US 2005012662 W US2005012662 W US 2005012662W WO 2005112564 A3 WO2005112564 A3 WO 2005112564A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disclosed
germline
making
humanized
Prior art date
Application number
PCT/US2005/012662
Other languages
French (fr)
Other versions
WO2005112564A2 (en
Inventor
Jeffrey Schlom
Eduardo A Padlan
Syed V S Kashmiri
Original Assignee
Us Gov Health & Human Serv
Kashmiri Rafia Mehdi
Jeffrey Schlom
Eduardo A Padlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Kashmiri Rafia Mehdi, Jeffrey Schlom, Eduardo A Padlan filed Critical Us Gov Health & Human Serv
Publication of WO2005112564A2 publication Critical patent/WO2005112564A2/en
Publication of WO2005112564A3 publication Critical patent/WO2005112564A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides methods of designing humanized monoclonal antibodies having minimal immunogenicity and retained antigen binding affinity, by using human germline sequences as templates for each of the variable light chain and variable heavy chain regions (CDRs and frameworks). The present disclosure also provides humanized COL-1 antibodies generated by the disclosed methods. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
PCT/US2005/012662 2004-04-15 2005-04-15 Germline and sequence variants of humanized antibodies and methods of making and using them WO2005112564A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56278104P 2004-04-15 2004-04-15
US60/562,781 2004-04-15
US58083904P 2004-06-18 2004-06-18
US60/580,839 2004-06-18

Publications (2)

Publication Number Publication Date
WO2005112564A2 WO2005112564A2 (en) 2005-12-01
WO2005112564A3 true WO2005112564A3 (en) 2007-01-18

Family

ID=35428728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012662 WO2005112564A2 (en) 2004-04-15 2005-04-15 Germline and sequence variants of humanized antibodies and methods of making and using them

Country Status (1)

Country Link
WO (1) WO2005112564A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
CN101479381B (en) 2006-03-31 2015-04-29 中外制药株式会社 Method for control of blood kinetics of antibody
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
KR101922788B1 (en) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
US8748356B2 (en) * 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
WO2010107109A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN103298937B (en) 2010-11-17 2016-05-25 中外制药株式会社 There is the polyspecific antigen binding molecules of the function of the function that replaces blood coagulation factor VIII
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
MX2016003616A (en) 2013-09-27 2016-07-21 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer.
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
MA41294A (en) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE
CN107108729A (en) 2015-02-05 2017-08-29 中外制药株式会社 The antibody of antigen-binding domains comprising ion concentration dependence, FC region variants, the binding antibodies of IL 8, and its application
TWI805046B (en) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Use of IL-6 receptor antibody for preparing pharmaceutical composition
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
KR102538749B1 (en) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
WO2003002607A1 (en) * 2001-06-27 2003-01-09 Shawn Shui-On Leung Reducing immunogenicities of immunoglobulins by framework-patching
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
WO2004022717A2 (en) * 2002-09-05 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
WO2003002607A1 (en) * 2001-06-27 2003-01-09 Shawn Shui-On Leung Reducing immunogenicities of immunoglobulins by framework-patching
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
WO2004022717A2 (en) * 2002-09-05 2004-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE PASCALIS ROBERTO ET AL: "Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 169, no. 6, 15 September 2002 (2002-09-15), pages 3076 - 3084, XP002402423, ISSN: 0022-1767 *
GONZALES NOREEN R ET AL: "SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.", MOLECULAR IMMUNOLOGY. JUL 2004, vol. 41, no. 9, July 2004 (2004-07-01), pages 863 - 872, XP002402422, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
WO2005112564A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
SG151284A1 (en) Antibodies against ccr5 and uses thereof
GEP20074222B (en) Antibodies to cd40
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
LUC00025I1 (en)
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
NZ593068A (en) IL-18 antibody
WO2005118635A3 (en) Anti-cd3 antibodies and methods of use thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
RU2011116112A (en) BSPECIFIC ANTI-EGFR / ANTI-IGF-1R ANTIBODIES
WO2005121179A3 (en) Transferrin receptor antibodies
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
NZ547157A (en) Interferon Alpha Antibodies and their uses
WO2006084075A3 (en) Adam-9 modulators
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
DK1716181T3 (en) CDR repaired antibodies
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
NZ596042A (en) Humanized anti-factor d antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase